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Abstract.  Amyloid precursor protein (APP) secretase 
plays a pivotal role in the processing of APP since its 
activity precludes the formation of amyloid peptide in 
Alzheimer's Disease. The identity and the subcellular 
localization of this enzyme are at this moment un- 
known. It is also unclear how APP escapes the activ- 
ity of this enzyme when amyloid is formed. We have 
previously shown that APP-secretase activity is not in- 
hibited by exogenously added proteinase inhibitors of 
different specificity (De Strooper, B., E  Van Leuven, 
and H. Van Den Berghe.  1992. FEBS (Fed.  Eur.  Bio- 
chem.  Soc.) Lett.  308:50-53).  We show here that the 
primary amine methylamine inhibits the secretion of 
APP into the medium.  Furthermore,  we show that a 
truncated form of APE devoid of the cytoplasmic do- 
main,  is more efficiently cleaved and secreted than 
wild-type APE which together with the methylamine 
block, shows that APP-secretase is located in a late 
compartment of the default constitutional  secretion 
pathway.  The sorting signals in the cytoplasmic do- 
main of APP are therefore important  in the deviation 
of APP from the secretase pathway.  Finally we show 
that mutation of Arg609 to Asp in combination with 
Lys612 to Glu makes APP a less efficiently cleaved 
substrate for APP-secretase. 
The results are discussed in the context of recent 
findings on the targeting of APP and a parallel is drawn 
with some lysosomal glycoproteins that follow similar 
pathways. 
T 
HE amyloid precursor proteins (APP's) 1 are a family 
of very similar,  alternatively  spliced proteins,  coded 
by a single gene on chromosome 21, and expressed in 
brain,  and in lesser amounts  in other tissues  (Kang et al., 
1987; Kitaguchi et al., 1988; Tanzi et al., 1988; Ponte et al., 
1988; De Sauvage and Octave, 1989; Golde et al., 1992; I<6- 
nig et al., 1992). Most APP isoforms contain the/3-amyloid 
region, a short peptide of  42-43 amino acids, which is a con- 
stituent of the amyloid plaques in the brains of Alzheimer pa- 
tients (Glenner and Wong, 1984; Masters et al.,  1985). Be- 
cause several single amino acid substitutions in the APP gene 
are linked to familial early onset Alzheimer's  disease,  a di- 
rect link between the formation  of amyloid plaques and the 
pathogenesis  of  this  devastating  disorder  is  very  likely 
(Goate et al., 1991; Chartier-Harlin  et ai.,  1991; Murrell et 
al.,  1991; Yoshioka et al.,  1991; Fernandez-Madrid et al., 
1991; Naruse et al.,  1991; Levy et al.,  1990;  Van Broek- 
hoven et al.,  1990;  Hendriks et al.,  1992).  Insight  in the 
cellular metabolism of APP is therefore of uttermost impor- 
tance for the understanding  of the pathogenesis  of Alzhei- 
mer's disease. 
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1. Abbreviation  used in this paper:  APE amyloid precursor protein. 
The/~-amyloid sequence is located partially  in  the ex- 
tracellular  and partially in the transmembrane domain of the 
APP protein.  The processing of APP, as studied in different 
cell types cultured in vitro,  includes  a proteolytic cleavage 
step in the amyloid sequence (Weidemann et al., 1989; Siso- 
dia et al.,  1990; Esch et al.,  1990; Anderson et al.,  1991; 
Wang et al.,  1991). This step, mediated by an elusive APP 
secretase (Selkoe,  1989, 1990; Sisodia, 1992), yields a solu- 
ble (secreted)  form of APP and a small integral  membrane 
protein (Oltersdorf et al.,  1990). Because cleavage of APP 
occurs  in  the  ~/-amyloid sequence  itself,  cleavage  and 
amyloid formation  are mutually exclusive processes. 
The available information  shows that APP is transported 
via the Golgi-complex to the cell surface and released in a 
soluble form into the medium (Weidemarm et al.,  1989). 
The cytoplasmic carboxyl-terminal domain remains  mem- 
brane  anchored  (Oltersdorf et al.,  1990)  and  disappears 
slowly, probably by endocytosis via coated pits, mediated by 
the NPXY consensus signal in the cytoplasmic part of the 
protein (Chela et al.,  1990). In some cells,  APP appears as 
an intact protein at the cell surface (Weidemann et al., 1989; 
Haass et al., 1992a). This intact APP is endocytosed (proba- 
bly mediated by the same signal) and degraded in the lyso- 
somes. This pathway is potentially  amyloidogenic  (Haass et 
al.,  1992a,b;  Estus et al.,  1992; Golde et al.,  1992; Shoji 
et al.,  1992).  A  third  pathway  is possible in which APP 
enters directly an endosomal-lysosomal compartment, from 
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ported to the lysosomes.  This has been demonstrated for 
lysosomal membrane glycoprotein lgpl20 (Harter and Mell- 
man,  1992). 
Two important questions with respect to the intracellular 
routing of APP remain unanswered at this moment: first, the 
exact localization of APP-secretase, and second, how intact 
APP can escape from secretase activity. Either processing 
by  secretase  is  not  very efficient or  part  of the  APP  is 
deviated towards a pathway which does not contain secre- 
tase.  Finally, although there is evidence (Benowitz et al., 
1989; Haass et al.,  1992a; Estus et ~1., 1992; Golde et al., 
1992) that intact APP can appear in the lysosomes (where 
it could be potentially amyloidogenic), it remains unclear 
whether  APP  enters  this  compartment directly  from the 
Golgi-apparatus,  or  passes  obligatory via  the  cell  mem- 
brane. 
The present work was  intended to examine these ques- 
tions. Indirect evidence is provided for an intracellular local- 
ization of APP-secretase in a compartment of the constitu- 
tional secretion pathway where it cleaves overexpressed APP 
very efficiently. We find that secretion of normal APP and 
of a  truncated form of APP is  inhibited by methylamine. 
Combined Arg(609) to Asp and Lys(612) to Glu mutations 
make APP a less good substrate for APP-secretase. We dem- 
onstrate that deletion of part of the cytoplasmic domain of 
APP results in the very efficient secretion of APP, which sup- 
ports the conclusion that APP-secretase is localized on the 
(default) constitutional secretion pathway.  Our findings are 
discussed in the light of recently published data on the me- 
tabolism and cellular targeting of APP and on the targeting 
of some lysosomal proteins. 
Materials and Methods 
Cell Culture, Metabolic Labeling and 
Double-immune Precipitation 
Neuro 2a neuroblastoma cells were obtained from the American Type  Cul- 
ture Collection (Rockville,  MD) and cultured in DME/F12 (GIBCO BRL, 
Gaithersburg, MD) with 10% FCS.  For metabolic labeling experiments, 
400,000 cells were seeded into a T25 flask (Falcon Labware, Becton, Dick- 
inson and Company, Oxnard, CA) and after 24 h medium was replaced  by 
DME/F12 without serum. In these conditions cells develop overnight  multi- 
ple and long neuritic extensions  (De Strooper et ai.,  1992). 
Pulse labeling of the cells was done with 150/~Ci per ml [3SS]methionine 
(NEN) in methionine-free  DME for 20 rain. After a chase-period performed 
in DME/FI2, APP was isolated  by double-immune  precipitation  as described 
previously (De Strooper et al., 1991a). The polyclonal antibody B2/3 against 
murine APP was raised in rabbits by immunization with a fusion protein 
between the T7 gene 10 protein (pGEMEX, Promega Corp., Madison, WI) 
and the carboxy terminal part of the mouse APP695 starting from amino 
acid 321 (De Strooper et al.,  1991b). The antibody was used at a dilution 
1/16. In the conditions specified below, immune precipitation of APP was 
quantitative both from cell extracts  and from medium (result not shown). 
Carboxy-terminai specific antibodies (112292) were generously provided by 
Dr. C. Abraham (Boston University School of Medicine, Boston, MA) and 
used at 1/50 dilution.  Precipitation of APP was quantitative as illustrated 
in Fig. 9 b. mAb 22CII against APP was obtained from Boehringer Mann- 
heim Corp. (Germany). 
After incubation for 1 h with the first antibody, the immune complexes 
were precipitated overnight  with protein A Sepharose (Pharmacia, Uppsala, 
Sweden) saturated with polycional swine anti-rabbit antibodies (Dakopatts, 
Dako S. A., Denmark). 
Stock  solutions of methylammoniumchloride, chloroquine,  and  am- 
moniumacetate were sterilized and stored in small aliquots at -20"C until 
used.  The solutions were added directly to the culture medium of the cells 
30 min before the start of the experiment. 
COS-1 cells were cultured in DME/F12 medium containing 10% FCS. 
For transfection, cells were plated at 700,000 ceils in a "125 flask and after 
24 h, processed as described below. All experiments were performed on 
COS-1 calls before the tenth passage. 
Secretion of APP695 and mutated forms into the medium was followed 
by SDS-PAGE (7 % gels, unless otherwise indicated)  by applying  normal- 
ized amounts of complete medium directly or after double-immune precipi- 
tation of APP.  Normalization was done towards/3-galactosidase  activity, 
which was cotransfected  with the APP-constructs  (see below).  Fluorogra- 
pby was done as described (De Strooper et al.,  1991a). Quantitative den- 
sitometry was performed with a Personal Densitometer (Molecular Dy- 
namics, Inc., Sunnyvale, CA). The density of the bands was calculated  by 
volume integration as described by the rnarmfacturer.  Individual experi- 
ments were analyzed by comparing absolute values.  For calculations  con- 
cerning the mean of the secretion rate of APP over several independent ex- 
periments at once, absolute densitometric volumes were converted towards 
relative volumes by normalization towards the volume obtained for APP695 
after 2 h in the separate experiments.  Linearity of the obtained signals was 
evaluated by measuring the signals from serial dilution curves of metabolic 
labeled APP and by exposing  autoradiograms for variable time intervals 
(4-60 h in the experiments  shown in this publication). 
The sensitivity of the double-immune precipitation assay is illustrated in 
Fig.  1, which shows the result of double-immune precipitations on equal 
amounts of progressively  diluted medium of COS-I ceils transfected  with 
APP695.  It was found that up to 1% of the amount of APP present in the 
samples used is readily detectable after an exposure  of 60 h. 
Transformation of COS-1 Cells 
COS-1 cells were transfected with the DEAE-dextran method (Luthman and 
Magnusson, 1983).  Briefly, cells were washed twice with PBS and incu- 
bated with a mixture of DME/FI2, 20 ~g/ml DEAE-dextran, I0 tLg/ml  plas- 
mid PSG5 containing the APP-constructs  as described below and 5/~g/mi 
pSVL/3-galactosidase  plasmid (Promega Corp., Madison, WI). After 2 h, 
the cells were washed twice with PBS, and then treated with DME/F12 con- 
taining 0.15 mM chloroquine.  After 2 h, cells were washed and further cul- 
tured in complete medium for 48 h. In all steps,  antibiotics (ampieillin- 
streptomycin,  GIBCO BRL) were included in the culture medium. 
The pSG5 plasmid contains the early SV40 promotor, a ~-globin intron, 
the cloned APP or its mutants and a polyadenylation  signal and directs the 
synthesis of APP-RNA.  The pSVL plasmid directs the RNA synthesis for 
/~-galactosidase from a SV40 late promotor. The/5-galactosidase activity 
was  assessed  with the /3-gaiactosidase  enzyme assay  system  (Promega 
Corp.) and used as a measure for the transfection efficiency. 
Transfection of COS-1 cells with pSG5 containing the eDNA for murine 
c~2-macroglobulin was done as described (Van Leuven et al.,  1993). 
Plasmids and Constructions 
Mouse APP695 was isolated  by screening  a mouse brain eDNA library 
(Uni-Zap  TM  XR,  Stratagene  Inc.,  La Jolla, CA)  as a  full insert clone in 
Figure I.  Sensitivity of the immune precipitation assay. Double- 
immune precipitations with B2/3 (1/16) were performed on a series 
of diluted medium of COSl-cells transfected with APP695 (see leg- 
end  to  Fig.  9  for  further  experimental  details).  Exposure  was 
30 h. (Lane 1) Standard amount of medium of transfected COS-1 
ceils used in the experiments is taken as 1/1. (Lane 2) 1/2 dilution; 
(lane 3) 1/4 dilution; (lane 4) 1/10 dilution; (lane 5) 1/20 dilution; 
(lane 6)  1/100 dilution; (lane 7) no label added. The weak signal 
in lane 6 is clearly observed after 60 h of exposure of the autoradio- 
gram, which shows that the immune precipitation assay is able to 
detect levels of APP 100 times lower than the level in the control 
experiments. 
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Figure 2. Eukaryotic expression vectors for APP695, APP695R/KMUT and APP695TRUNC. A shows the plasmid pSG5 with its essential 
features. Mouse APP695 (De Strooper et al., 1991b) was cloned into the multiple cloning site as a Spel fragment. The/~-amyloid region 
(hatched) and the transmembrane domain (white box) are indicated, together with putative sorting signals in the cytoplasmic domain. B 
shows the/3A4-amyloid sequence and the exact cleavage site of APP-secretase. The mutated amino acids in APP695R/KMUT are boxed. 
The right displays the cytoplasmic domain of  APP. The position of  the stop-codon in APP695TRUNC is indicated, together with the deleted 
putative sorting signals. C shows the synthetic oligoduplex used to make APPTRUNC. 
pBluescript. The deduced amino acid sequence is 97.6 % identical to the hu- 
man sequence (De Strooper et al.,  1991b).  APP695 was cloned as a Spel 
fragment in the adapted multiple cloning site ofa pSG5-plasmid (Stratagane 
Inc.) under the control of the early SV40 promotor (Fig. 2 A). 
APP695R/KMUT was prepared by deletion ofa BgllI and NarI fragment 
(see Fig. 2 A) and replacing it with a synthetic oligonucleotide cassette con- 
taining the mutations (boxed, Fig. 2 B). The presence of the mutations was 
confirmed by  sequencing.  The  mutated  APP695R/KMUT  was  further 
cloned as a  Spei fragment in pSG5. 
APP695TRUNC was prepared by partial digesting pBluescript/APP695 
with SalI (Fig. 2 A), and introduction of a synthetic oligonucleotide cassette 
containing a stop codon, a Seal and an unique HpaI site (Fig. 2 C). The 
correct insertion in the second Sail site was selected for and confirmed by 
sequencing. The APP695trunc construct was cloned in pSG5 as described 
above. 
Synthetic oligonucleotides were synthesized on a 391 DNA synthesizer 
(Applied Biosystems, Inc., Foster City, CA). For the APP695R/KMUT a 
sense oligonucleotide of 105  nucleotides (spanning nucleotides  1770  to 
1874 of APP695, numbering as in De Strooper et al.,  1991b) and an an- 
tisens¢  of 103 nucleotides (nucleotides 1774 to 1876) were made. The codon 
at nueleotide 1825 (CGC, Arg609) was mutated to CAT (Asp). The codon 
at nucleotide 1834 (AAA, Lys612) was mutated to GAG (Glu). The cassette 
used for APP695TRUNC is shown in Fig. 2 (7. 
Results 
Methylamine Inhibits APP Secretion in 
Neuroblastoma  Cells 
Mouse neuro 2a neuroblastoma cells, differentiated as de- 
scribed in Materials and Methods, secreted APP in their cul- 
ture medium as shown in Fig. 3 a. We found previously that 
the addition of proteinase inhibitors of all classes of pro- 
teinases, including the broad spectrum proteinase inhibitor 
o~2-macroglobulin (Van  Leuven,  1982) to the culture me- 
dium had no effect on APP-secretion (De Strooper et al., 
1992),  which  suggested that APP-secretase is  located in- 
tracellularly.  We tested therefore, inhibitors of lysosomal 
and endosomal proteinases. In the presence of  relatively high 
concentrations of primary amines, the secretion of APP de- 
creased to ~50% of the control with chloroquine and with 
ammoniumacetate but to 15 % of the control with methyl- 
amine (Fig. 3 b). However, the effect of chloroquine seemed 
small because total incorporation of label into cellular pro- 
tein, assessed by TCA precipitation, was also decreased to 
'~50%.  Methylamine, on the other hand,  was clearly less 
toxic because in all experiments its effect on APP secretion 
was much more pronounced than its effect on protein synthe- 
sis. Moreover, the inhibition of secretion was dose dependent 
and was always paralleled by an increase of cell associated 
immune precipitable APP (Fig. 3 c). This demonstrated that 
the effect of methylamine was caused not by an inhibition of 
APP synthesis, but by an inhibition of APP secretion into the 
medium. To observe the effect, it was necessary to pretreat 
the cells for 30 min, indicating an intracellular site of action. 
Methylamine Inhibits APP Secretion in COS-Cells 
To avoid the heterogeneity of the APP-proteins in the neuro- 
De Strooper ¢t al. Modulation of Amyloid Precursor Protein Secretion  297 Figure 3. APP-secretion in differentiated  Neuro 2a neuroblastoma cells. Cells were pulse-labeled  for 20 min and chased either as indicated 
or for 2 h. Double-immune precipitation  was done with polyclonal antibodies  B2/3 against a fusion protein of mouse APP with the T7 
gene 10 protein.  It recognizes epitopes on both sides of  the secretase cleavage site and was used at a 1/16 dilution.  Precipitation is quantitative 
as evaluated by consecutive immune precipitations  (not shown). A 7 % homogeneous gel was used.  (a) Appearance of APP in the medium. 
After 2 h, the secretion of APP is maximal. The reason for the slight decrease of APP at 4 h is unknown, but could be caused by proteolytic 
degradation, or uptake by the cells (Knauer and Cunningham, 1984). (b) Effect of primary amines and chloroquine on APP-secretion after 
2 h of chase. (Co) Control; (MA) 30 mM methylamine;  (Chq) 0.3 mM chloroquine; (AA) 50 mM ammoniumacetate. At these high concen- 
trations only methylamine has a significant  effect on APP-secretion.  (c) Dose-response curve with methylamine.  (Left) Double-immune 
precipitations  of the cell extracts  show a concentration dependent  accumulation of APP reactive  material  in the cells.  Total incorporated 
label  varied  ,~20%  in the four lanes.  (Right) Shows a concentration dependent  inhibition  of secretion  of APP into the medium. 
blastoma cells (Fig.  3, De Strooper et al.,  1992) and to be 
able to test mutated forms of APE we decided to use tran- 
sient transfection of  COS-1 cells which express only very low 
levels of  endogenous APP (Fig. 4 a, lane/). These cells were 
transfected with constructs containing mouse APP695 under 
the control of the early SV40 promotor, allowing synthesis, 
maturation and secretion of APP695 by these cells  (Fig.  4 
a,  lane 2).  In this  system also,  methylamine (30 mM)  in- 
hibited  efficiently  the  secretion  of mouse  APP695.  More- 
over, the electrophoretic mobility of the cellular APP695 in 
the methylamine treated cells was identical to that of the un- 
treated controls (Fig.  4  b). 
Truncation of the Cytoplasmic Domain Increases the 
Secretion of  APP 
The cytoplasmic domain of APP contains the NPXY con- 
sensus sequence for coated pit mediated endocytosis (Chen 
et al.,  1990). A stop codon was introduced upstream of this 
signal to delete most of the cytoplasmic domain (Fig. 2 B). 
This  truncated  APP695  was  secreted  more  efficiently  by 
transfected COS-cells than the wild-type APP695  (Figs.  5 
and 7). Significantly, methylamine was again observed to be 
an efficient inhibitor of this process (Fig. 6 a). The secretion 
(but not the biosynthesis)  of transfected murine ot2-macro- 
globulin, was also inhibited by methylamine, indicating that 
the methylamine effect is not limited to APP (Fig.  6  b). 
An Arg609 to Asp and Lys612 to Glu Mutation in the 
Secretase Recognition Site of  APP695 Decreases the 
Rate of  APP695 Cleavage and APP695 Secretion into 
the Medium 
The secretase recognition site in APP695 is located COOH 
terminal of a  lysine residue,  preceded two amino acids up- 
stream by another basic residue (arginine in mouse and histi- 
dine in humans), (Sisodia et al., 1990; Esch et al., 1990; An- 
derson et al.,  1991; Wang et al.,  1991; Yamada et al.,  1987; 
De Strooper et al.,  1991b).  Most other amino acids in this 
region are either acidic or not charged (Fig. 2 B). We opted 
to mutate both basic residues and replaced the arginine609 
Figure 4.  Mouse APP695 in COS-1 cells.  (a)  COS-1 cells  were 
transfected  with APP695 or pSVL/$Gal as detailed  in Material  and 
Methods.  Total cell extracts  were applied  on SDS-PAGE and im- 
munoblotted with mAb 22C11 (Weidemann et al.,  1989). Negligi- 
ble to very weak immunoreaction is observed in the control cells 
transfected  with pSVL/3gal ~Gal), whereas in the APP695 trans- 
fected  cells  (APP), a  strong  reaction of the precursor form and 
weak reaction of the maturated form is seen.  (b) Cells, transfected 
as in a, were metabolically labeled  for 2 h in the presence (+) or 
absence  (-)  of  30  mM  methylamine  (IDA). Double-immune 
precipitations  were performed with antibody B2/3 (1/16) against the 
mouse APP fusion protein, either on the medium (ME/)) or on the 
cell  extracts  (CELL). Methylamine  inhibits  clearly  secretion  of 
APE  The mobility of cell associated  APP in both methylamine 
treated  and untreated  cells is identical  in 7% SDS-PAGE. The ac- 
cumulation of APP in the methylamine  treated  cells  is obvious in 
less  exposed  autoradiograms. 
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fected with either  APP695  (APP), APP695R/KMUT  (R/K) and 
APP695TRUNC  (Trunc) were metabolically  labeled  for 60 min 
and then processed by double-immune  precipitations  on the cells 
(CELL)  or on the medium (MED)  with antibody B2/3 (1/16). Notice 
the  decreased  secretion  of the APPR/KMUT and the  enhanced 
secretion of APPTRUNC, while the synthesis of precursor APP is 
in the  three  instances  almost equal.  Analysis  was done  on 7% 
SDS-PAGE. 
by an aspartic acid and lysine612  by a  glutamic acid (see 
Materials and Methods). 
When this construct (APP695R/KMUT)  was transfected 
into COS cells,  APP695  secretion was decreased although 
not completely abolished (Fig.  5). 
Quantitative  measurements  of secreted  APP  were  per- 
formed to compare the effect of  the mutations to that of  methyl- 
amine (Fig. 7). After 2 h, the secretion of APP695TRUNC 
and  APP695R/KMUT  was,  respectively,  181  and  56%  of 
control APP695  (Fig.  7).  The secretion of APP695  in the 
presence of 30  mM methylamine was  11%  of the  control 
(Fig. 7). All measurements were normalized towards cotrans- 
fected/3-galactosidase activity in the cell extracts. 
The Bulk of CeU-associated APP is Uncleaved 
To investigate whether cleaved APP could accumulate in any 
of the conditions tested,  we performed immune precipita- 
tions  with  an  antiserum  against  cleaved  and  intact  APP 
(rabbit antiserum B2/3) and with an antiserum against the 
carboxyl terminus of APP (rabbit antiserum R2292) on con- 
tinuous metabolically labeled COS cells. As shown in Fig. 
8,  no major differences were observed in immune precipi- 
tated material with either antiserum, from cells transfected 
with APP695  and treated with methylamine or from cells 
transfected  with  APP695R/KMUT,  when  compared  with 
controls transfected with APP695.  As anticipated,  the car- 
boxy terminal directed antibodies  R2292  did  not  immune 
precipitate APP695TRUNC  (result not shown). 
These results indicated qualitatively that most of the cell 
associated APP contained  the 20  carboxy-terminal amino 
acids, and is thus uncleaved. 
The accumulation of APP695  in the presence of methyl- 
Figure 6.  Inhibition of secretion of APP695TRUNC  in the pres- 
ence of 30 mM methylamine.  (a)  COS-1 ceils,  transfected  with 
APP695TRUNC, were metabolically labeled either without or with 
addition of 30 mM methylamine. Double-immune precipitation on 
comparable amounts of  either the cell extracts (CELL) or the media 
(MED) revealed that secretion is strongly decreased in the presence 
of  methylamine. There is also an increase in cell associated material 
in the presence of methylamine. Analysis was done on a 7 % SDS- 
PAGE. (b) COS-1 cells, transfected with pSG5 vector containing 
the  cDNA for mouse  a2-macroglobulin,  were metabolically  la- 
beled for 1 h in the absence or presence of 30 mM methylamine. 
Double-immune  precipitation  was  performed with  rabbit  anti- 
mouse c~:-macroglobulin antiserum (Nordic),  diluted  1/16. Anal- 
ysis was done on 6-20% gradient SDS-PAGE.  Note the 185-kD, 
the  165-kD, and the 35-kD subunits of mouse a2-macroglobulin 
as described in detail elsewhere (Van Leuven et al.,  1992). In the 
presence of methylamine secretion  is strongly inhibited. 
amine was investigated in further quantitative detail by pulse 
chase analysis. As shown in Fig. 9 a, an important increase 
(250%) of cell associated APP695 is observed after a chase 
of 2 h in the presence of methylamine when compared to the 
control. No major differences were observed in the material 
precipitated from cell extracts with antiserum B2/3 against 
complete APP or R2292  against the carboxyl terminus of 
APP. In contrast, the carboxyl terminus specific antibodies 
did not precipitate APP from the culture medium (Fig. 9 a). 
Because  it  remained  possible  that  a  small  amount  of 
cleaved  APP  in  the  extracts  was  obscured  by  the  large 
amount  of  uncleaved  APP  in  the  cells,  cell  extracts  of 
methylamine treated cells were first cleared by three con- 
secutive immune precipitations with the carboxyl-terminus 
directed  antibody.  This  effectively removed all  uncleaved 
APP from the cell extract as shown in Fig. 9 b. Thereafter, 
an immune precipitation was performed with the antibody 
against complete APP.  A  small, but significant amount of 
APP was precipitated (1-5 % when compared to the amount 
of uncleaved APP initially precipitated with R2292).  As a 
positive control, the same experiment was done on cell ex- 
tract combined with an equivalent quantity of medium from 
untreated cells, containing cleaved APP. As shown in Fig. 9 
b, cleaved APP was, as anticipated, quantitatively recovered 
at the end of the assay. This experiment excluded proteolysis 
or other artifacts during the assay. 
That the double-immune precipitation assay was sensitive 
and linear in a range up to 1% of the material used, was al- 
ready demonstrated in Fig.  1. 
De Strooper et al. Modulation of Amyloid Precursor Protein Secretion  299 Figure Z Secretion of APP695TRUNC, APP695 and APP695R/KMUT in the medium of  transfected  COS-1 cells. (a) COS-1 cells, trans- 
fected with the indicated expression vectors for the APP constructs and B-galactosidase were metabolically labeled for 2 h. At the indicated 
time intervals,  100 #1 of medium was taken for analysis.  At the end of the experiment,  cell layers were solubilized  and B-galactosidase 
activity  was measured by a colorimetric assay (see Material and Methods).  This was taken as a measurement for transfection  efficiency 
and a normalized amount of medium was directly applied on 7% SDS-PAGE for every time point. The autoradiogram labeled ~-galactosi- 
dase is a negative control, b shows the appearance of APP in the medium as determined by densitometry of autoradiograms displayed 
in a. To allow comparison between separate  experiments,  obtained densitometric volumes  (see Material  and Methods)  were normalized 
to the volume obtained at 2 h for APP695. For the APP constructs the mean +  SEM for four independent  transfection  experiments  are 
indicated.  For APP695+30 mM methylamine only three independent  experiments  were performed. 
Figure 8.  Analysis of cell associated  APP in COS-cells.  The cell 
extracts of transfected  COS-cells metabolically labeled for 2 h and 
obtained from the quantitative  experiments  in Fig. 6 were double- 
immune precipitated  with polyclonal antibody B2/3 at a dilution 
1/16. B2/3 recognizes epitopes at both sides of the secretase cleav- 
age site of murine APP and precipitates  therefore both cleaved and 
uncleaved  APP (T).  Polyclonal  antibody R2292 (kindly  provided 
by Dr. C. Abraham, Boston University School of Medicine,  Bos- 
ton, MA) against the carboxyl terminus of APP, recognizes only 
epitopes at the carboxyterminal side of  the cleavage site. It was used 
Discussion 
Insight in the cellular processing of APP will eventually lead 
to the understanding at the molecular level of the formation 
of  the arnyloid peptide and of  amyloid plaques in Alzheimer's 
disease  and  other  cerebral  disorders.  The  APP  secretase 
plays a pivotal role in the processing of APE because only 
APP  that  escapes  this  activity  can  give  rise  to  amyloid 
peptide. 
We have previously demonstrated that proteinase inhibi- 
tors specific for the four major classes of proteinases were 
not able to inhibit  secretase  activity at the cell  surface of 
mouse neuroblastoma  cells.  This  led us to the conclusion 
that secretase is located in an intracellular compartment (De 
Strooper  et  al.,  1992).  Only  methylamine  inhibited  effi- 
ciently  the  secretion  of APP  into  the  medium  (Fig.  3). 
Methylamine treatment led also to the accumulation of two 
APP-forms in Neuro 2a cells. It is unclear whether they rep- 
at a 1/50 dilution.  Corresponding lanes are labeled (C) in the figure. 
Above each lane, the construct used to transfect  the cells  is indi- 
cated. Shorter exposures  of the autoradiograms did also not reveal 
any quantitative  differences.  R2292 did not react with APP695- 
TRUNC (result  not shown). 
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treated cells. COS-1 cells transfected with APP695 and/$-galactosi- 
dase containing vectors, were pulse labeled for 20 min and chased 
for 2 h in the absence or presence of 30 mM methylamine. Double- 
immune precipitation was done on comparable amounts of cell ex- 
tracts  or medium  in all  lanes.  Normalization  was done  towards 
B-galactosidase activity. (a) Normalized  amounts of cell extracts 
(Cell) or medium (Med) were immune precipitated with antibody 
B2/3 (1/16 dilution) or R2292 (1/50 dilution) and precipitates were 
analyzed on 6% SDS-PAGE. Notice the slower metabolism of APP 
in COS-1 cells compared to neuroblastoma cells (Fig. 3 c), the in- 
crease of cell associated APP after methylamine treatment (lane 3 
compared with lane 1) concomitant  with the decreased  secretion 
of APP into the medium (lane 7 compared with lane 5). Most of 
the cell associated APP is recognized by antiserum B2/3 (CELL, 
lanes labeled T) as well as by antiserum  R2292 (CELL, lanes la- 
beled  C). R2292 does not react with cleaved APP (compare lane 
6 with lane 5). (b) Identical amounts of cell extracts from methyl- 
amine treated  cells  (a, lanes 3 and 4) were supplemented either 
with  buffer (CELL,  lanes  1-4) or with an equivalent amount  of 
medium of  untreated cells (CELL + MED, lanes 5-8). The extracts 
were immune precipitated three times with antibody R2292 to re- 
move all APP containing the carboxyterminal part and finally with 
antibody B2/3 to precipitate any remaining cleaved APP. Note that 
after three sequential immune precipitations all APP reacting with 
R2292 has been removed. A small quantity (1-5 % of the material 
precipitated  in lane  1)  is,  however, immune  precipitated  in the 
fourth step with B2/3, which indicated that a minor amount of cell 
resent  cleaved and  uncleaved  forms of APP,  alternatively 
spliced  forms  of  the  APP-mRNA  or  different  stages  of 
glycosylation of APP.  To avoid this problem and to test the 
effect of mutations in APP on secretion, we decided to use 
transient transfection in the COS-system and restricted the 
study to only one form, APP695. Transfected COS cells pro- 
duced precursor and mature forms of APP, and secreted APP 
into their medium. Consistent with the observations in the 
neuroblastoma cells, methylamine inhibited APP secretion 
also in transfected COS cells. 
Primary amines such as methylamine, ammoniumacetate, 
and chloroquine act by alkalinization of intracellular acidic 
compartments and are therefore used to  inhibit lysosomal 
degradation. These drugs inhibit however also recirculation 
of  endocytosed  cell  membrane  receptors  from  the  en- 
dosomal compartment towards the cell surface (Van Leuven 
et al., 1980) and cleavage and secretion of proteins along the 
default secretory pathway in hepatocytes (Oda and Ikehara, 
1985;  Oda  et  al.,  1986;  Lammers and  Jamieson,  1989). 
While all these drugs have similar effects on lysosomal pro- 
cessing  of proteins,  we  find  here  that  methylamine has  a 
more  pronounced  effect on  the  cleavage and  secretion  of 
APP. As discussed below, this methylamine block is located 
in the late acidic compartments of the default secretion path- 
way and inhibits also the constitutive secretion of the pro- 
teinase  inhibitor  ct2-macroglobulin.  The  exact  molecular 
mechanism awaits further investigation. 
Human  APP  follows  the  normal  constitutive  secretion 
pathway into the Golgi apparatus, where maturation of gly- 
cosyl residues is followed by cleavage and secretion of soluble 
APP (Weidemann et al.,  1989). It is not clear whether after 
maturation of the carbohydrate chains,  APP enters the en- 
dosomal compartment or follows the default pathway taken 
by most integral membrane and constitutively secreted pro- 
teins.  In the first option,  secretase would be located in the 
endosomes, in the second case, secretase could be located 
either in the late Golgi, in the TGN or in a transport vesicle. 
Putative sorting signals in the cytoplasmic domain of APP 
are expected to be important in that respect and their deletion 
would favor the default secretion pathway. As demonstrated 
here, a truncated form of APP is cleaved and secreted more 
efficiently than the wild-type form. Hence, we conclude that 
APP secretase is located in the secretion pathway. The fact 
that  methylamine inhibited  the  secretion  of the  truncated 
APP695, led us to the conclusion that the methylamine block 
of APP secretion is also located in the constitutive secretion 
pathway. This conclusion is corroborated by the observation 
that the constitutive secretion of mouse tx2-macroglobulin 
transfected in COS-1 cells (Van Leuven et al., 1993) was also 
inhibited by methylamine treatment (Fig. 6 b). This methyl- 
amine block of protein secretion is located in the acidic, late 
Golgi  compartment,  at  least  in  hepatocytes  (Oda  et  al., 
1986; Lammers and Jamieson, 1989). Methylamine did not 
interfere with glycosyl-residue maturation in these cells, but 
inhibited very efficiently the proteolytic cleavage of proalbu- 
associated APP is cleaved. The other half of the gel (lanes 5-8) il- 
lustrates that externally added cleaved APP is quantitatively recov- 
ered.at the end of this assay. If APP would accumulate as a cleaved 
form in methylamine  treated  cells,  the  magnitude  of the  signal 
should be comparable  to that obtained  in lane 4. 
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chored sialyltransferase in the late Golgi (Oda and Ikehara, 
1985; Oda et al., 1986; Lammers and Jamieson, 1989). Be- 
cause methylamine inhibited also the secretion, but not the 
cleavage  of haptoglobin, which is proteolytic processed in 
the ER, the effect of methylamine on protein secretion is 
more general than interference with proteolytic maturation 
alone (Oda et al., 1986). Although our findings in COS cells 
showed no major differences between immune precipitated 
APP695  from control or methylamine-treated transfected 
COS cells after 2 h continuous labeling (Fig. 4 b) and showed 
accumulation of APP with the mobility of mature APP in 
methylamine treated cells after a 2-h chase (Fig. 9 a), it re- 
mains to be further investigated whether the methylamine 
block on the secretion pathway in COS cells observed in our 
study is similarly restricted to the late Golgi. Our results in- 
dicate however that the cell-associated APP accumulating in 
the presence of methylamine is mainly uncleaved. This led 
us to the conclusion that methylamine blocks the transport 
of APP  towards  the  secretase  compartments  or  inhibits 
directly  the  activity  of  secretase  in  the  secretase  com- 
partment. 
Our  previous  published  data,  which  showed that pro- 
teinase inhibitors acting at the cell surface did not inhibit 
APP secretion (De Strooper et al., 1992),  indicated that se- 
cretase is located intracellularly. The fact that small amounts 
of cleaved APP are associated with cell extracts (Fig. 9 b) 
is also compatible with an intracellular localization of secre- 
tase, although endocytosis from the medium remains a pos- 
sibility as well. Recent evidence suggests however that this 
soluble APP is indeed produced intracellularly (Sambamurti 
et al.,  1992).  Because the methylamine block of protein 
secretion is located in the late, acidic Golgi compartments 
of the default secretion pathway, we conclude that secretase 
is mainly located in this compartment or in the transport 
vesicles towards the cell surface. The fact that almost no ma- 
ture APP695 is detected in transfected COS cells (Fig. 4 a), 
suggests also that final glycosyl maturation and cleavage of 
APP are closely associated processes in time and therefore 
in space (Weidemann et al.,  1989). 
Based on the observation that surface labeled APP was 
secreted almost immediately into the culture medium after 
warming up cell layers to 37°C, it was recently suggested that 
secretase is present at the cell surface (Sisodia, 1992).  This 
finding is not necessarily in contradiction with our observa- 
tions: it is conceivable that secretase is not completely lim- 
ited to the late compartment of the default secretion path- 
way. Because it is well established that escape and retrieval 
processes of proteins in the different compartments of this 
pathway are the rule, a similar mechanism can explain why 
minor amounts of APP at the cell surface can be cleaved 
without being endocytosed. The fact that proteinase inhibi- 
tors added at the cell surface have no major effects on the 
cleavage of APP, indicate however that the bulk of the pro- 
cessing takes place intracellularly (De Strooper et al., 1992, 
1993). 
Endocytosis, recently demonstrated for APP (Haass et al., 
1992a), mediated by the consensus NPXY signal in the cyto- 
plasmic domain, could target intact APP at the cell surface 
towards the lysosomes. Interestingly, the NPXY  signal is 
also  present  in  lysosomal acidic  phosphatase,  a  protein 
which recirculates 10-15 times between the endosomes and 
the cell surface before reaching its final destination in the 
lysosomes (Braun et al., 1989; Eberle et al., 1991). Deletion 
of this signal in the APP695trunc mutant yielded systemati- 
cally more soluble APP695 in the medium compared to the 
wild-type APP (Figs. 5 and 7). Because similar amounts of 
APP695-vector were used in all experirnents, and because 
cotransfection with a  /~-galactosidase  construct ruled out 
large variations in transfection efficiency, we conclude that 
wild-type APP695 (and APP695R/K) was deviated from the 
default secretion pathway. Because APP is not sorted towards 
the regulated secretion pathway (Overly et al,. 1991), the al- 
ternative pathway must enter the endosomal-lysosomal com- 
partment. Lysosomal glycoprotein 120 is an example of a 
glycoprotein that follows such a direct pathway from the late 
Golgi towards the endosomes. This pathway is saturable and 
the sorting signal is Gly-Tyr (Harter and Mellman, 1992). 
Interestingly, the NPTY  sequence in APP is preceded by 
Gly-Tyr.  Protein phosphorylation in PC12  cells stimulates 
the secretion of APP into the culture medium (Buxbaum et 
al., 1990; Caporaso et al., 1992). If phosphorylation occurs 
on one of the two tyrosines or on the threonine present in the 
GYENPTY sequence of APP, this could render the signal 
inactive,  a  situation  mimicked by  the  truncated  mutant 
APP695TRUNC. 
The sorting signals targeting APP away from the secretase 
pathway towards a potential amyloidogenic pathway (Haass 
et al., 1992a,b; Estus et al., 1992; Golde et al., 1992; Shoji 
et al., 1992), explain at a molecular level the paradox of  APP 
following two different pathways in the cell. 
Until now, it has been found very difficult to interfere with 
APP-secretase activity (Maruyama et al., 1991; De Strooper 
et al.,  1992).  It has recently been demonstrated that muta- 
tions which disrupt the or-helicoidal  structure around the 
APP cleavage site decrease the cleavage  of APP (Sisodia, 
1992). We describe here a new secretion mutant in which the 
a-helicoidal propensity is not significantly altered. The two 
amino  acid  substitutions  which  resulted  in  a  much  less 
efficient secretion  of APP,  have mainly an  effect on the 
charge distribution in that region,  changing two positive 
residues  towards  two  negative ones.  The  cell  associated 
APP695R/KMUT displayed a slightly lower mobility than 
wild-type APP695.  Whether the two amino acid substitu- 
tions, or whether differences in posttranslational modifica- 
tions are responsible for this mobility shift remains to be in- 
vestigated. It is anticipated however, that this, and the other 
slow secretion mutants (Sisodia et al.,  1992),  are excellent 
tools to investigate the metabolic and cellular pathways fol- 
lowed by APP once it has escaped APP-secretase activity. 
Because these pathways are potentially amyloidogenic, this 
will help our understanding of #-amyloid formation and 
hopefully Alzheimer's disease. 
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